Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,234 matching trials from the live ClinicalTrials.gov search.
Conditions
Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Metastatic Breast Cancer
Interventions
Palbociclib, Tamoxifen
Drug
Lead sponsor
Oana Danciu, MD
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Chicago, Illinois • Lansing, Michigan • Minneapolis, Minnesota + 4 more
Conditions
Advanced Solid Tumor and Lymphoma Malignancies
Interventions
TAK-659
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
5
States / cities
Sarasota, Florida • Chicago, Illinois • Nashville, Tennessee + 2 more
Conditions
Non-Hodgkin's Lymphoma
Interventions
ABBV-291
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Huntersville, North Carolina • Eugene, Oregon • Austin, Texas + 2 more
Not listed Phase 1Phase 2 Interventional

ALG.APV-527 First-in-human Study

NCT05934539
Conditions
Solid Tumor
Interventions
ALG.APV-527
Drug
Lead sponsor
Aptevo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Port Saint Lucie, Florida
Conditions
Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
Interventions
Ziftomenib, Midazolam, Itraconazole
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
20
States / cities
Gilbert, Arizona • Los Angeles, California • Jacksonville, Florida + 16 more
Conditions
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Interventions
9vHPV Vaccine, mRNA-1273 Vaccine
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
9 Years to 11 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more
Conditions
Healthy Participants
Interventions
Ad35.RSV.FA2, Ad26.RSV.FA2, Placebo
Biological · Drug
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)

NCT02443740
Conditions
Healthy
Interventions
BIIB118
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant
Interventions
OP-3136, Fulvestrant, Palazestrant
Drug
Lead sponsor
Olema Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Gilbert, Arizona • Aurora, Colorado • Sarasota, Florida + 8 more
Conditions
AML (Acute Myeloid Leukemia)
Interventions
CHM-029
Drug
Lead sponsor
Charm Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Duarte, California • New Haven, Connecticut • Grand Rapids, Michigan + 2 more
Conditions
Advanced Solid Tumor
Interventions
BG-C9074, Tislelizumab, Bevacizumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 2 more
Conditions
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
Interventions
REGN10597, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • North Haven, Connecticut + 7 more
Conditions
Advanced Solid Tumor
Interventions
STP1002
Drug
Lead sponsor
ST Pharm Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Denver, Colorado • Evanston, Illinois
Conditions
MTAP-deleted Solid Tumors
Interventions
BAY 3713372
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 12 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LC542019 in Healthy Subjects and Subjects With T2DM

NCT06333977
Conditions
Healthy, Diabetes Mellitus, Type 2
Interventions
LC542019, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Advanced Cancer
Interventions
BMS-986288, Nivolumab, Regorafenib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Costa Mesa, California • Orange, California • Aurora, Colorado + 3 more
Conditions
Carcinoma, Small Cell
Interventions
GSK2879552
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • Columbus, Ohio • Nashville, Tennessee
Conditions
Schizophrenia
Interventions
AMG 579, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Conditions
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions
BBI-940, Fulvestrant
Drug
Lead sponsor
Boundless Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
8
States / cities
Los Angeles, California • Lake Success, New York • Austin, Texas + 4 more
Conditions
Advanced Solid Malignancies
Interventions
CFI-402411, Pembrolizumab
Drug
Lead sponsor
Treadwell Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • New Haven, Connecticut + 6 more
Conditions
Patients With Multiple Myeloma Experiencing a, First or Second Relapse
Interventions
IPH2101 combined to lenalidomide
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio + 2 more
Conditions
Advanced Solid Tumor
Interventions
ZL-1211
Drug
Lead sponsor
Zai Biopharmaceutical (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Scottsdale, Arizona • Lynwood, California • Indianapolis, Indiana + 7 more
Conditions
Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions
M4112
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
New Haven, Connecticut • Houston, Texas • San Antonio, Texas
Conditions
Advanced Solid Tumor
Interventions
BGB-C354, Tislelizumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 2 more